PARP-1 inhibitors could also be used in the therapy of inflammatory diseases, including neurological disorders, as inhibition of ADP-ribosylation activity lessens neurodegeneration and demyelination in several animal disease models (e.g., Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis). The gene discussed is PARP1; the disease is early-onset autosomal dominant Alzheimer disease.